Search

Your search keyword '"Mazeu, I"' showing total 50 results

Search Constraints

Start Over You searched for: Author "Mazeu, I" Remove constraint Author: "Mazeu, I"
50 results on '"Mazeu, I"'

Search Results

1. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

2. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

3. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

4. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

5. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

6. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

7. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

8. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

9. Gender differences in the use of cardiovascular interventions in HIV?positive persons; the D:A:D Study

10. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

11. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

12. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

13. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

14. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

15. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

16. Liver-related death among HIV/hepatitis C virus-co-infected individuals

17. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

18. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

19. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

20. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

21. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

22. Infection-related and -unrelated malignancies, HIV and the aging population

23. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

24. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients

25. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

26. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

27. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

28. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

29. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

30. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

31. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

32. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study

33. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

34. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

35. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

36. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change

37. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

38. Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

39. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

40. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

41. Dialysis and renal transplantation in HIV-infected patients: a European survey

42. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

43. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

46. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study

47. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

48. Trastuzumab resistance: Bringing tailored therapy to the clinic

Catalog

Books, media, physical & digital resources